Pranali Ravikumar

Pranali Ravikumar

Auto-generated profile, based on publicly available information

Pranali Ravikumar

Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SOShannon K. Oda
Shannon K. Oda
KAKristin G. Anderson
Kristin G. Anderson
PRPranali Ravikumar
Pranali Ravikumar
PBPatrick Bonson
Patrick Bonson
NGNicolas M. Garcia
Nicolas M. Garcia
PGPhilip D. Greenberg
Philip D. Greenberg
Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be limited by restrictive tumor microenvironments (TMEs). For example, Fas ligand is commonly overexpressed in TMEs and induces apoptosis in tumor-infiltrating, Fas receptor–positive lymphocytes. We engineered immunomodulatory fusion proteins (IFPs) to enhance ACT efficacy, combining an inhibitory receptor ectodomain with a costimulatory endodomain to convert negative into positive signals. We developed a Fas-4-1BB IFP that replaces the Fas intracellular tail with costimulatory 4-1BB. Fas-4-1BB IFP-engineered murine T cells exhibited increased pro-survival signaling, proliferation, antitumor function, and altered metabolism in vitro. In vivo, Fas-4-1BB ACT eradicated leukemia and significantly improved survival in the aggressive KPC pancreatic cancer model. Fas-4-1BB IFP expression also enhanced primary human T cell function in vitro. Thus, Fas-4-1BB IFP expression is a novel strategy to improve multiple T cell functions and enhance ACT against solid tumors and hematologic malignancies.


3 April 2023
Verified
Other
Open access
NSNathan Singh
Nathan Singh
YLYong Gu Lee
Yong Gu Lee
OSOlga Shestova
Olga Shestova
PRPranali Ravikumar
Pranali Ravikumar
KHKatharina E. Hayer
Katharina E. Hayer
MRMarco Ruella
Marco Ruella
Impairment of death receptor signaling results in resistance to CART19.